State AIDS Drug Assistance Programs’ Contribution to the US Viral Suppression, 2015–2022
Clinical Infectious Diseases · 20.05.2026 · 82 (5) · e967-e973
DOI: 10.1093/cid/ciag034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 25.03.2026. Verfasst von Kathleen A McManus und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Viral Load, HIV Infections, Acquired Immunodeficiency Syndrome, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Background
State AIDS Drug Assistance Programs (ADAPs) provide human immunodeficiency virus (HIV) medication access for people with HIV (PWH) with low incomes in the United States. We quantified the proportion of viral suppression (VS) that is from ADAP clients for 2015–2022.
Methods
For 2015–2022, we obtained viral load (VL) test results and VS data from publicly available, jurisdiction-level data on ADAP clients and PWH. We report descriptive statistics including the proportion of PWH with a VL who had VS and were supported by ADAPs.
Results
After excluding jurisdictions with missing data, PWH who were included in the analysis for each year was 63.7%–96.4%. Viral suppression for PWH each year was 60%–66.3%. Viral suppression for ADAP clients was 81.2%–91.4%. In all years, compared to all PWH, a lower proportion of ADAP clients had a reported VL and a higher proportion had VS. Over 2015–2022, the average proportion of PWH who were ADAP clients was 23.1%, the proportion of PWH with VLs who were ADAP clients was 22.2%, and the proportion of PWH with VS who were ADAP clients was 30.8%.
Conclusions
Almost a third of the entire VS rate was from ADAP clients, despite ADAP serving less than 25% of PWH. A much higher proportion of ADAP clients achieved VS, compared to PWH. AIDS Drug Assistance Programs’ impact is not due to ADAP clients being over represented among PWH with reported VLs. AIDS Drug Assistance Program does not directly receive any federal Ending the HIV Epidemic (EHE) Initiative funding. Policymakers should examine how ADAPs can support the EHE Initiative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases and International Health, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
- NASTAD, Washington, District of Columbia, USA.
- School of Nursing, University of Virginia, Charlottesville, Virginia, USA.
- Division of Pediatric Hematology/Oncology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
- Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.
ORCID-Profile: Kathleen A McManus, Amber Steen, Elizabeth T Rogawski McQuade
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
Zitieren
APA
McManus, K. A., Killelea, A., Rogers, E. Q., Liu, F., Horn, T., Steen, A., Keim-Malpass, J., Hamp, A., & McQuade, E. T. R. (2026). State AIDS Drug Assistance Programs’ Contribution to the US Viral Suppression, 2015–2022. Clinical Infectious Diseases, 82(5), e967-e973. https://doi.org/10.1093/cid/ciag034
Vancouver
McManus KA, Killelea A, Rogers EQ, Liu F, Horn T, Steen A, et al. State AIDS Drug Assistance Programs’ Contribution to the US Viral Suppression, 2015–2022. Clinical Infectious Diseases. 2026;82(5):e967-e973. doi:10.1093/cid/ciag034
BibTeX
@article{McManus2026,
author = {McManus, Kathleen A and Killelea, Amy and Rogers, Erin Q and Liu, Feng and Horn, Tim and Steen, Amber and Keim-Malpass, Jessica and Hamp, Auntré and McQuade, Elizabeth T Rogawski},
title = {State AIDS Drug Assistance Programs’ Contribution to the US Viral Suppression, 2015–2022},
journal = {Clinical Infectious Diseases},
year = {2026},
volume = {82},
number = {5},
pages = {e967--e973},
doi = {10.1093/cid/ciag034}
}
EUVIMED